| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
282,380,000 |
| Market
Cap: |
358.62(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.06 - $3.28 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Erasca is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Co.'s primary product candidates are ERAS-007 (its oral ERK1/2 inhibitor) and ERAS-601 (its oral SHP2 inhibitor), which together comprise its MAPKlamp. The extracellular signal-regulated kinases (ERK), ERK1 and ERK2, belong to a family of serine-threonine kinases that regulate cellular signaling, and comprise the terminal node of the RAS/MAPK pathway. Co. is pursuing a clinical development plan across multiple tumor types for ERAS-007, which Co. refers to as its HERKULES series of clinical trials.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
2,120,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$3,972,364 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Multani Pratik S |
|
– • – |
2025-05-23 |
4 |
GA |
$0.00 |
$0 |
I/I |
6,200 |
6,200 |
|
- |
|
| Multani Pratik S |
|
– • – |
2025-05-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,200 |
166,666 |
|
- |
|
| Garner Ebun |
General Counsel & Corp. Sec. |
• – – |
2024-12-13 |
4 |
A |
$1.56 |
$8,963 |
D/D |
5,731 |
21,174 |
|
- |
|
| Chacko David M. |
CFO and CBO |
• – – |
2024-12-13 |
4 |
A |
$1.56 |
$19,275 |
D/D |
12,324 |
262,187 |
|
- |
|
| Garner Ebun |
General Counsel & Corp. Sec. |
• – – |
2024-06-14 |
4 |
A |
$1.56 |
$8,938 |
D/D |
5,715 |
21,174 |
|
- |
|
| Chacko David M. |
CFO and CBO |
• – – |
2024-06-14 |
4 |
A |
$1.56 |
$4,906 |
D/D |
3,137 |
262,187 |
|
- |
|
| Casdin Alexander W. |
Director |
– • – |
2024-05-21 |
4 |
B |
$2.27 |
$181,920 |
D/D |
80,000 |
573,974 |
2.39 |
10% |
|
| Chacko David M. |
CFO and CBO |
• – – |
2023-12-15 |
4 |
A |
$1.59 |
$11,886 |
D/D |
7,478 |
246,726 |
|
- |
|
| Garner Ebun |
General Counsel & Corp. Sec. |
• – – |
2023-12-15 |
4 |
A |
$1.59 |
$8,660 |
D/D |
5,448 |
9,728 |
|
- |
|
| Start Valerie Denise Harding |
Director |
– • – |
2023-12-06 |
4 |
B |
$1.85 |
$18,480 |
I/I |
10,000 |
20,000 |
2.1 |
3% |
|
| Lim Jonathan E |
Chairman & CEO |
• • • |
2023-12-06 |
4 |
B |
$1.72 |
$478,418 |
I/I |
278,150 |
12,899,360 |
2.64 |
3% |
|
| Lim Jonathan E |
Chairman & CEO |
• • • |
2023-12-05 |
4 |
B |
$1.69 |
$1,217,761 |
I/I |
721,850 |
12,899,360 |
2.64 |
10% |
|
| Casdin Alexander W. |
Director |
– • – |
2023-12-04 |
4 |
B |
$1.66 |
$49,785 |
D/D |
30,000 |
493,974 |
2.39 |
19% |
|
| Lim Jonathan E |
Chairman & CEO |
• • • |
2023-10-05 |
4 |
B |
$2.03 |
$2,026,000 |
I/I |
1,000,000 |
19,456,216 |
2.64 |
-18% |
|
| Lim Jonathan E |
Chairman & CEO |
• • • |
2023-06-08 |
4 |
B |
$2.75 |
$275,000 |
I/I |
100,000 |
18,396,216 |
2.64 |
-11% |
|
| Casdin Alexander W. |
Director |
– • – |
2023-04-10 |
4 |
B |
$2.76 |
$55,230 |
D/D |
20,000 |
463,974 |
2.39 |
-8% |
|
| Lim Jonathan E |
Chairman & CEO |
• • • |
2023-03-28 |
4 |
B |
$2.84 |
$284,000 |
I/I |
100,000 |
18,296,216 |
2.64 |
-4% |
|
| Chacko David M. |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
A |
$3.89 |
$7,169 |
D/D |
1,750 |
239,248 |
|
- |
|
| Wei Lin |
Chief Medical Officer |
• – – |
2023-02-01 |
4 |
A |
$3.89 |
$7,169 |
D/D |
1,750 |
315,812 |
|
- |
|
| Garner Ebun |
General Counsel & Corp. Sec. |
• – – |
2023-02-01 |
4 |
A |
$3.89 |
$9,791 |
D/D |
2,390 |
4,280 |
|
- |
|
| Lim Jonathan E |
Chairman & CEO |
• • • |
2023-01-10 |
4 |
B |
$3.86 |
$231,420 |
I/I |
60,000 |
20,256,222 |
2.64 |
-26% |
|
| Bristol James Arthur |
Director |
– • – |
2022-12-21 |
4 |
B |
$4.14 |
$82,800 |
I/I |
20,000 |
20,000 |
2.1 |
-33% |
|
| Start Valerie Denise Harding |
Director |
– • – |
2022-12-21 |
4 |
B |
$4.64 |
$46,400 |
I/I |
10,000 |
10,000 |
2.1 |
-33% |
|
| Casdin Alexander W. |
Director |
– • – |
2022-12-15 |
4 |
B |
$4.87 |
$97,490 |
D/D |
20,000 |
443,974 |
2.39 |
-45% |
|
| Lim Jonathan E |
Chairman & CEO |
• • • |
2022-12-14 |
4 |
B |
$4.99 |
$199,600 |
I/I |
40,000 |
20,196,222 |
2.64 |
-47% |
|
34 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (3.05%) 
